Swedish researchers planning to hold Covid-19 nasal vaccine trial in Bangladesh

Swedish researchers are gearing up to seek permission from Bangladeshi authorities to hold clinical trials of a nasal COVID-19 vaccine in the country, reported the Dhaka Tribune.

According to Bangladeshi experts associated with the trial, the vaccine developed by the Karolinska Institute yielded good results in pre-clinical trials.

Sweden's Immune System Regulation (ISR) Holding is set to submit the application to the Bangladesh Medical Research Council sometime next week for clearance to hold the trial, media reports say.

The ISR has also signed a deal with a Bangladeshi firm UniMed UniHealth Pharmaceuticals in July for local production of the vaccines.

The trials are expected to be carried out on 180 health workers of Mugda Medical College Hospital.